Uveal Melanoma - Pipeline Review, H2 2018

Uveal Melanoma - Pipeline Review, H2 2018


  • Products Id :- GMDHC10896IDB
  • |
  • Pages: 235
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Uveal Melanoma-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uveal Melanoma-Pipeline Review, H2 2018, provides an overview of the Uveal Melanoma (Oncology) pipeline landscape.

Uveal melanoma, the most common intraocular tumor, is a disease in which cancer (malignant) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include dark spot on the iris, glaucoma, eye pain and eye redness. Uveal melanoma is more common in people who have atypical mole syndrome, dysplastic nevus syndrome, and ocular or oculodermal melanocytosis. Treatment includes surgery, radiation and proton therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uveal Melanoma-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 15, 8, 1 and 7 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 1, 1, 1 and 1 molecules, respectively.

Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Uveal Melanoma (Oncology).

- The pipeline guide reviews pipeline therapeutics for Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Uveal Melanoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Uveal Melanoma (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 5

Uveal Melanoma-Overview 6

Uveal Melanoma-Therapeutics Development 7

Uveal Melanoma-Therapeutics Assessment 14

Uveal Melanoma-Companies Involved in Therapeutics Development 24

Uveal Melanoma-Drug Profiles 34

Uveal Melanoma-Dormant Projects 218

Uveal Melanoma-Discontinued Products 219

Uveal Melanoma-Product Development Milestones 220

Appendix 230

List of Figures

Number of Products under Development for Uveal Melanoma, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

List of Tables

Number of Products under Development for Uveal Melanoma, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Uveal Melanoma-Pipeline by AbbVie Inc, H2 2018

Uveal Melanoma-Pipeline by Aeglea BioTherapeutics Inc, H2 2018

Uveal Melanoma-Pipeline by Bellicum Pharmaceuticals Inc, H2 2018

Uveal Melanoma-Pipeline by Bristol-Myers Squibb Co, H2 2018

Uveal Melanoma-Pipeline by Cleveland BioLabs Inc, H2 2018

Uveal Melanoma-Pipeline by Delcath Systems Inc, H2 2018

Uveal Melanoma-Pipeline by Eli Lilly and Co, H2 2018

Uveal Melanoma-Pipeline by Exelixis Inc, H2 2018

Uveal Melanoma-Pipeline by Iconic Therapeutics Inc, H2 2018

Uveal Melanoma-Pipeline by Immunocore Ltd, H2 2018

Uveal Melanoma-Pipeline by Inventiva, H2 2018

Uveal Melanoma-Pipeline by Iovance Biotherapeutics Inc, H2 2018

Uveal Melanoma-Pipeline by Novartis AG, H2 2018

Uveal Melanoma-Pipeline by PEP-Therapy SAS, H2 2018

Uveal Melanoma-Pipeline by Pfizer Inc, H2 2018

Uveal Melanoma-Pipeline by Plexxikon Inc, H2 2018

Uveal Melanoma-Pipeline by Polaris Pharmaceuticals Inc, H2 2018

Uveal Melanoma-Pipeline by Syndax Pharmaceuticals Inc, H2 2018

Uveal Melanoma-Pipeline by TESARO Inc, H2 2018

Uveal Melanoma-Pipeline by Viralytics Ltd, H2 2018

Uveal Melanoma-Dormant Projects, H2 2018

Uveal Melanoma-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AbbVie Inc

Aeglea BioTherapeutics Inc

Bellicum Pharmaceuticals Inc

Bristol-Myers Squibb Co

Cleveland BioLabs Inc

Delcath Systems Inc

Eli Lilly and Co

Exelixis Inc

Iconic Therapeutics Inc

Immunocore Ltd

Inventiva

Iovance Biotherapeutics Inc

Novartis AG

PEP-Therapy SAS

Pfizer Inc

Plexxikon Inc

Polaris Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

TESARO Inc

Viralytics Ltd

Uveal Melanoma Therapeutic Products under Development, Key Players in Uveal Melanoma Therapeutics, Uveal Melanoma Pipeline Overview, Uveal Melanoma Pipeline, Uveal Melanoma Pipeline Assessment

select a license
Single User License
USD 2000 INR 137580
Site License
USD 4000 INR 275160
Corporate User License
USD 6000 INR 412740

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com